Search research articles
Contact Us
Filters
Showing results (331-340 of 524) with videos related to
Page
of 53
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
David R Spigel, Afshin Dowlati, Yuanbin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2013
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors
Antonio Jimeno, Glen J Weiss, Wilson H Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Noura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 5, 2019
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
Morana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, et al.
Science Advances
|
April 10, 2024
Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions
Joseph B Hiatt, Anna-Lisa Doebley, Henry U Arnold, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 27, 2022
POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC
Marina K Baine, Christopher A Febres-Aldana, Jason C Chang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 29, 2006
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma
Helen J Ross, Lowell L Hart, Paul M Swanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2018
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer
Ken Suzawa, Michael Offin, Daniel Lu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 30, 2019
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices
Natasha Rekhtman, Patrice Desmeules, Anna M Litvak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
Michael Offin, Joseph M Chan, Megan Tenet, et al.
Page
of 53
Search research articles
Search
Showing results (331-340 of 524) with videos related to
Sort By:
Page
of 53
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
David R Spigel, Afshin Dowlati, Yuanbin Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2013
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors
Antonio Jimeno, Glen J Weiss, Wilson H Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Noura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 5, 2019
Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
Morana Vojnic, Daisuke Kubota, Christopher Kurzatkowski, et al.
Science Advances
|
April 10, 2024
Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions
Joseph B Hiatt, Anna-Lisa Doebley, Henry U Arnold, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 27, 2022
POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC
Marina K Baine, Christopher A Febres-Aldana, Jason C Chang, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 29, 2006
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma
Helen J Ross, Lowell L Hart, Paul M Swanson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2018
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer
Ken Suzawa, Michael Offin, Daniel Lu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 30, 2019
Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices
Natasha Rekhtman, Patrice Desmeules, Anna M Litvak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 23, 2019
Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
Michael Offin, Joseph M Chan, Megan Tenet, et al.
Page
of 53